Scarica l'app Stockscreener
447.43
0.10%
0.43
Dopo l'orario di chiusura:
447.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$447.00
Aprire:
$444.77
Volume 24 ore:
1.30M
Relative Volume:
1.22
Capitalizzazione di mercato:
$58.65B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-181.15
EPS:
-2.47
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
-1.49%
1M Prestazione:
+11.36%
6M Prestazione:
+83.73%
1 anno Prestazione:
+76.31%
Intervallo 1D:
$442.73
$456.18
Intervallo di 1 settimana:
$441.50
$457.29
Portata 52W:
$205.87
$469.81
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Sentiment analysis tools applied to Alnylam Pharmaceuticals Inc.July 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
How high can Alnylam Pharmaceuticals Inc. stock goOptions Play & Community Consensus Picks - Newser
The Strategic Value of Novartis' $5.2 Billion Argo Biopharma Licensing Deal in the RNAi Cardiovascular Therapeutics Space - AInvest
Technical analysis overview for Alnylam Pharmaceuticals Inc. stockJuly 2025 Outlook & Stepwise Trade Signal Implementation - Newser
How institutional ownership impacts Alnylam Pharmaceuticals Inc. stockJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Technical signs of recovery in Alnylam Pharmaceuticals Inc.July 2025 Volume & Fast Gaining Stock Reports - Newser
How to use a screener to detect Alnylam Pharmaceuticals Inc. breakoutsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.Earnings Performance Report & Technical Pattern Alert System - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performanceShort Setup & Real-Time Volume Analysis Alerts - Newser
Will breakout in Alnylam Pharmaceuticals Inc. lead to full recovery2025 Earnings Surprises & Safe Entry Point Alerts - Newser
What MACD and RSI say about Alnylam Pharmaceuticals Inc.Earnings Summary Report & Weekly High Potential Alerts - Newser
What to expect from Alnylam Pharmaceuticals Inc. in the next 30 days2025 Trading Recap & Scalable Portfolio Growth Methods - Newser
Key resistance and support levels for Alnylam Pharmaceuticals Inc.Earnings Recap Summary & Daily Stock Momentum Reports - Newser
Using fundamentals and technicals on Alnylam Pharmaceuticals Inc.2025 Geopolitical Influence & Weekly Top Performers Watchlists - Newser
Published on: 2025-09-03 01:05:50 - Newser
Multi asset correlation models including Alnylam Pharmaceuticals Inc.2025 Historical Comparison & Stock Market Timing Techniques - Newser
Alnylam Pharmaceuticals: Amvuttra's Launch And Ongoing Clinical Progress Are Positives - Seeking Alpha
Alnylam Pharmaceuticals Inc.’s volatility index tracking explained2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
What does recent volatility data suggest for Alnylam Pharmaceuticals Inc.2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
Chart overlay techniques for tracking Alnylam Pharmaceuticals Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
What’s the analyst consensus on Alnylam Pharmaceuticals Inc.Stock Surge & Weekly Return Optimization Plans - khodrobank.com
Alnylam Shares Edge Up 0.11% on $480M Volume (Rank 222nd) as RNAi Pipeline Drives 70%+ Total Return - AInvest
How sentiment analysis helps forecast Alnylam Pharmaceuticals Inc.Quarterly Performance Summary & Weekly Watchlist for Consistent Profits - Newser
Will Alnylam Pharmaceuticals Inc. outperform small cap indexesTrade Entry Report & Verified Momentum Watchlists - khodrobank.com
Is Alnylam Pharmaceuticals Inc. forming a breakout pattern2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - khodrobank.com
Strategies to average down on Alnylam Pharmaceuticals Inc.July 2025 Breakouts & Verified High Yield Trade Plans - Newser
ALNY Stock: HC Wainwright & Co. Reiterates Buy Rating with $570 PT | ALNY Stock News - GuruFocus
Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio? - Yahoo Finance
Roche and Alnylam to take zilebesiran into Phase III hypertension trial - The Pharma Letter
Maraganore, Meanwell Launch Corsera, Their Third Act In Cardiovascular Disease - insights.citeline.com
Corsera Health Launches to Extend Healthspan by Predicting and Preventing Cardiovascular Disease - BioSpace
Alnylam reports new analysis from trial of Amvuttra for ATTR-CM - Yahoo Finance
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com
Startup Corsera Health aims to bring preventive heart medicine to the masses - BioPharma Dive
Alnylam founding CEO launches a new biotech to create 'world without cardiovascular disease' - The Business Journals
Does Alnylam Pharmaceuticals Inc. offer margin of safety2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - khodrobank.com
Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback - MSN
What’s next for Alnylam Pharmaceuticals Inc. stock priceVolume Spike & Free Daily Entry Point Trade Alerts - Newser
Buyback Watch: What are Alnylam Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Reactions & Fast Exit Strategy with Risk Control - khodrobank.com
What MACD and RSI say about Alnylam Pharmaceuticals IncJuly 2025 Big Picture & Growth-Oriented Investment Plans - Newser
Alnylam PharmaceuticalsNew Data from Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM - MarketScreener
Positive Outlook for Alnylam Pharma Amid Promising Cardiovascular Drug Developments and Strategic Partnerships - TipRanks
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win - Nasdaq
Can Alnylam Pharmaceuticals Inc. hit a new high this monthJuly 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Applying chart zones and confluence areas to Alnylam Pharmaceuticals Inc.Portfolio Update Report & Community Trade Idea Sharing Platform - Newser
Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension - insights.citeline.com
Best data tools to analyze Alnylam Pharmaceuticals Inc. stockJuly 2025 Reactions & Technical Pattern Alert System - Newser
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN
Published on: 2025-08-31 22:37:06 - Newser
Quantitative breakdown of Alnylam Pharmaceuticals Inc. recent move2025 Big Picture & AI Powered Trade Plan Recommendations - Newser
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.44%
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):